Jan 21, 2021
Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
Dec 11, 2020
Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Dec 08, 2020
Sutro Biopharma Announces Pricing of $126.0 Million Public Offering
Dec 07, 2020
Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
Dec 07, 2020
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Dec 03, 2020
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
Nov 24, 2020
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
Nov 18, 2020
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Nov 05, 2020
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
Sep 21, 2020
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
Sep 09, 2020
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Sep 03, 2020
Sutro Biopharma to Present at Two Upcoming Investor Conferences
Aug 25, 2020
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Aug 11, 2020
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
Aug 10, 2020
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aug 06, 2020
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
Jun 22, 2020
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Jun 09, 2020
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
May 21, 2020
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
May 11, 2020
Sutro Biopharma Announces Pricing of $85.3 Million Public Offering